血清ENAH在HBV相关肝癌患者中的表达及其临床意义
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

福建省自然科学基金项目(2020J01 1158) ;福州市“十四五”临床重点专科( 20220203 )


The expression and clinical significance of serum ENAH in patients with HBV related hepatocellular carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘要:目的探讨血清肌动蛋白调节剂(enablehomolog,ENAH)在乙型肝炎病毒相关性肝癌(HBV-HCC)中的临床意义。方法采用ELISA法检测67例HBV-HCC患者、20例非HBV相关肝癌患者( nonHBV-HCC)、60例慢性乙型肝炎(CHB)患者以及20例健康人对照(HC)血清ENAH水平,采用Spearman分析血清ENAH与患者肿瘤特征及实验室指标的相关性,绘制ENAH、甲胎蛋白(AFP)单独及二者联合检测( Logistic回归模型)的ROC曲线,并评估其对HBV-HCC的临床诊断价值。结果HBV-H0C、nonHBV-HCC、CHB患者和HC组血清ENAH的表达水平分别为8.5(7.0,8.9)ng/ mL.5.5(4.0, 6.0) ng/ mL .7.3(5.0,7.9)ng/mL和2.9(1.8 ,4.9)ng/mL,各组间差异有统计学意义(x2=71.36,P<0.001);血清ENAH与BCLC分期及肿瘤最大直径呈正相关(r分别为0.261和0.322 ,P值分别为0.035和0.008);血清ENAH、AFP单独及二者联合检测诊断HBV-HCC 的ROC曲线下面积( AUCROC )分别为0.808( 95%CI:0.735 ~ 0.868)、0.782( 95%CI:0.707 ~0.846)和0.838( 95%CI :0.768 ~0.894) ;血清ENAH诊断HBV-HCC敏感性和特异性分别为62. 69% ( 95% CI: 50.0% ~74.2%)和90.0% (95% Cl:81.2%~95.6%)。结论血清ENAH可作为一种潜在的HBV-HCC诊断和评估的血清学标志物。

    Abstract:

    Abstract : Objective To investigate the clinical significance of serum actin modulators ( enabled homolog, ENAH) in hepatitis B virus related hepatocellular carcinoma ( HBV-HCC). Methods The serum levels of ENAH were measured by ELISA in 67 patients with HBV-HCC, 20 patients with nonHBV-HCC, 60 patients with chronic hepatitis B ( CHB) and 20 healthy controls ( HC). Spearman's correlation analysis was used to examine the correlation between serum ENAH and tumor characteristics and laboratory indicators. Receiver operator curves ( ROCs) of ENAH, alpha fetoprotein ( AFP) and their combination ( Logistic regression model ) in diagnosis of HBV-HCC were plotted. Results The expression levels of serum ENAH in the patients with HBV-HCC, nonHBV-HCC, CHB and HC were 8.5(7.0, 8.9) ng/mL, 5.5(4.0, 6.0) ng/mL, 7.3(5.0, 7.9) ng/mL and 2.9(1.8, 4.9) ng/mL, respectively. The differences among the groups were statistically significant (x2 = 71.36,P<0.001 ). The serum ENAH was positively corelated with BCLC ( Barcelona Clinic Liver Cancer) and maximum tumor diameter (r=0.261 and 0.322, P= 0.035 and 0.008); The area under ROC ( AUCROL )of ENAH, AFP and their combination in diagnosis of HBV-HCC were 0.808( 95% CI:0.735-0.868), 0.782( 95% CI:0.707-0.846) and 0.838(95%CI: 0.768-0.894) , respectively. The sensitivity and speificity of ENAH in diagnosing HBV-HCC were 62. 69% ( 95% CI:50.0% -74.2% ) and 90.0%( 95%CI:81.2%-95.6% ), respectively. Conclusion Serum ENAH is a potential serological marker for diagnosis and evaluation of HBV-HCC.

    参考文献
    相似文献
    引证文献
引用本文

魏玉仙,彭菲,陈力,林英,柳丽娟,卓传尚.血清ENAH在HBV相关肝癌患者中的表达及其临床意义[J].临床检验杂志,2024,42(03):172-176

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-07-19
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-05-09
  • 出版日期:
您是第位访问者  苏ICP备12051282号-1
主管单位:江苏省医学会  出版单位:临床检验杂志
单位地址:江苏省南京市中央路42号  邮编:210008
电话:025-83620683 E-MAIL:lcjyzz@163.com
技术支持:北京勤云科技发展有限公司